BioSpace News Archive

Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N’s efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer’s disease in the U.S.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) today announced that four preclinical abstracts have been selected as poster presentations at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024).

Ascentage Pharma announced that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting.

Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.

BridgeBio Pharma, Inc. announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions.

LivaNova PLC announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 to be issued in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

CARBIOS announced that CARBIOS Active, its enzymatic solution for the biodegradation of PLA, is included in the U.S. Food and Drug Administration Inventory of Effective Food Contact Substances with the Assigned Food Contact Notification 2325, effective since 29 February 2024.

bit.bio, the company coding human cells for novel cures, announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to the Omnipod 5 Automated Insulin Delivery System at the 17th International Conference on Advanced Technologies & Treatments for Diabetes taking place March 6 – 9, 2024 in Florence, Italy, and online.

Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announced positive top-line efficacy data for NUZYRA® as post-exposure prophylaxis in a non-human primate model of inhalational anthrax.